Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases

다국어 초록 (Multilingual Abstract)

The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic therapy. Rivaroxaban is an oral factor Xa inhibitor, however its anticoagulation effects before or after administration of fibrinolytics in massive PE are still unknown. Two patents were admitted: 61-year-old woman with repeated syncope, and a 73-year-old woman was admitted with dyspnea and poor oral intake. Systemic arterial hypotension with radiologic confirmation led to a diagnosis of massive PE in both patients. Rivaroxaban was administered before in one, and after firbrinolytic therapy in the other. One showed similar efficacy of rivaroxaban with currently used anticoagulants after successful fibrinolysis, and the other one without antecedent administration of the fibrinolytic agent showed unfavorable efficacy of rivaroxaban.

참고문헌 (Reference)

1 EINSTEIN-PE Investigators, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism" 366 : 1287-1297, 2012

2 EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism" 363 : 2499-2510, 2010

3 Jaff MR, "Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association" 123 : 1788-1830, 2011

4 Piazza G, "Fibrinolysis for acute pulmonary embolism" 15 : 419-428, 2010

5 Kearon C, "Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines" 141 : e419S-e494S, 2012